In conclusion, the findings of this study provide strong evidence for the significant involvement of CD133 in chemotherapy resistance, not only in malignant brain tumors, as previously suggested, but also in low-grade gliomas, including pediatric PAs. The gene discussed is PROM1; the disease is brain cancer.